Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs Harbor

Two GLP-1 desks, one scoreboard. We put Invigor Medical and Harbor head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 183 · Grade C

Harbor

Visit Harbor Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 67 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make Harbor a bad call — it's best for readers who want adults seeking the lowest-cost compounded glp-1 with physician oversight and a 12-month money-back guarantee. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
36
Supply Reliability
88
83
Transparency
84
72
Access Breadth
82
50
Clinical Oversight
88
94
Track Record
90
78
Invigor MedicalBrief Score 88 · 67Harbor

Price, coverage & the tracker

Invigor MedicalHarbor
Brief Score88/100 (B+)67/100 (C)
Semaglutide$199/moFrom $99/mo (starting dose, compounded)
Tirzepatide$339/moFrom $149/mo (starting dose, compounded)
CoverageNot disclosedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

Harbor: New to the tracker on 1 August 2026. The published line reads From $99/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.